MTA-合作PRMT5抑制剂:通过基于结构的设计来切换机制
Kevin M Cottrell1, Douglas A Whittington1, Kimberly J Briggs1
1Tango Therapeutics, 201 Brookline Ave, Boston, Massachusetts 02215, United States.
Journal of medicinal chemistry
|February 7, 2025
概括
研究人员发现了新的化合物,可以通过MTAP删除选择性地杀死癌细胞. 这些化合物通过结合甲基氨酸 (MTA) 而不是S-adenosyl-l-methionine (SAM) 来向PRMT5蛋白,提供了一种新的治疗策略.
科学领域:
- 在瘤学瘤学.
- 药用化学 医学化学
- 分子生物学分子生物学
背景情况:
- 删除甲基铁氨酸酸化酶 (MTAP) 基因会导致其基质甲基铁氨酸 (MTA) 的积累.
- 在与PRMT5结合方面,MTA与S-adenosyl-l-methionine (SAM) 竞争,PRMT5是癌细胞增殖中至关重要的酶.
- 在PRMT5•SAM复合体上对PRMT5•MTA复合体的选择性抑制是针对MTAP删除癌症的策略.
研究的目的:
- 发现新型化合物,通过MTAP删除选择性向癌细胞.
- 将PRMT5抑制剂的结合机制从SAM合作转换为MTA合作.
- 通过基于结构的药物设计实现选择性杀死MTAP删除的癌细胞.
主要方法:
- 采用基于结构的药物设计来识别新化学实体.
- 专注于那些占据PRMT5未被MTA占用的SAM结合口袋的化合物.
- 工程化合物在PRMT5活性部位与Arg368形成键.
主要成果:
- 发现了以MTA合作方式与PRMT5结合的新化合物.
- 这些化合物占据SAM结合口袋的特定区域,与MTA结合不同.
- 设计的化合物可以选择性地向被MTAP删除的癌细胞.
结论:
- 成功开发了具有MTA合作结合机制的新型PRMT5抑制剂.
- 这些抑制剂选择性地向含有MTAP缺失的癌细胞.
- 这代表了对MTAP删除癌症的有前途的新治疗方法.
更多相关视频
相关概念视频
Cooperative Allosteric Transitions
7.8K
Cooperative allosteric transitions can occur in multimeric proteins, where each subunit of the protein has its own ligand-binding site. When a ligand binds to any of these subunits, it triggers a conformational change that affects the binding sites in the other subunits; this can change the affinity of the other sites for their respective ligands. The ability of the protein to change the shape of its binding site is attributed to the presence of a mix of flexible and stable segments in the...
7.8K
Structure-Activity Relationships and Drug Design
491
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
491
Covalently Linked Protein Regulators
6.8K
Proteins can undergo many types of post-translational modifications, often in response to changes in their environment. These modifications play an important role in the function and stability of these proteins. Covalently linked molecules include functional groups, such as methyl, acetyl, and phosphate groups, and also small proteins, such as ubiquitin. There are around 200 different types of covalent regulators that have been identified.
These groups modify specific amino acids in a protein....
These groups modify specific amino acids in a protein....
6.8K
Allosteric Regulation
57.5K
Allosteric regulation of enzymes occurs when the binding of an effector molecule to a site that is different from the active site causes a change in the enzymatic activity. This alternate site is called an allosteric site, and an enzyme can contain more than one of these sites. Allosteric regulation can either be positive or negative, resulting in an increase or decrease in enzyme activity. Most enzymes that display allosteric regulation are metabolic enzymes involved in the degradation or...
57.5K


